Northwind Pharma planning $10.5M expansion, 205 new hires
The Indianapolis company, located in the former St. Bernadette Catholic Church on the near-east side, plans to make the hires by the end of 2025.
The Indianapolis company, located in the former St. Bernadette Catholic Church on the near-east side, plans to make the hires by the end of 2025.
The proposals aim to lower prescription drug costs, promote competition among physicians and end the practice that allows for inaccurate medical billing in certain circumstances.
The number is down from 62 hospitals last year and 66 the before, but will still cost many hospitals money while they are still dealing with the strain of the pandemic that has overwhelmed resources and reduced their revenue and profits.
Net patient revenue for the first nine months of the year increased an undisclosed amount, driven by an increase in volumes in many areas. Patient days climbed 5% and admissions rose 5.7% during the period.
A high concentration of hospital, physician and insurance markets in Indiana have likely contributed to health care costs soaring 48% in a recent nine-year period, according to a new study commissioned by state lawmakers.
The federal No Surprises Act—which took effect Jan. 1 and protects patients from receiving surprise medical bills resulting from unexpected, out-of-network coverage—is already creating huge waves.
A new study released Thursday by the Rand Corp. showed that Hoosiers covered by employer health plans paid Indiana hospitals nearly three times—or 292%—of what Medicare would have paid for the same procedures.
When it comes to who is responsible for the high cost of health care, many of the organizations pointed fingers to different players in the wide-ranging industry.
House Speaker Todd Huston and Senate President Rodric Bray sent a joint letter Tuesday to 20 hospital and insurance executives, telling them to submit a plan by April 1 that would lower Indiana’s hospital prices to the national average or lower by 2025.
Indiana University Health, which charges the highest hospital fees in the Indianapolis area and is sitting on nearly $9 billion in cash and investments, said it is freezing prices through 2025 to help get in line with national average prices.
Separately, Dr. Aaron Kesselheim of Harvard University became the third member of an FDA advisory panel that opposed the drug to step down over the decision to approve it.
Health care practitioners and insurers are fighting over the hefty prices hospitals charge for specialty drugs to treat patients with cancer, vision loss, low white-blood-cell count and other serious diseases.
Haven, which was formed in 2018 by Amazon, Berkshire Hathaway and JPMorgan to attack soaring costs, will cease operations by the end of February.
A long-simmering dispute between Eli Lilly and Co. and safety-net hospitals across the nation over the price of prescription drugs has reached the boiling point.
A new study released Friday by the Rand Corp. found that Hoosiers covered by employer health plans paid Indiana hospitals three times what Medicare would have paid for the same procedures, exceeding the national rate of disparity.
Republican leaders of the Indiana General Assembly and Gov. Eric Holcomb have made addressing high health care costs a top priority this year, but the bills proposed to do so are unlikely to have much direct impact.
Three years after Indiana passed a law allowing doctors to prescribe drugs for patients without an in-person visit—using a computer, smartphone, video camera and similar technology—some health systems around the state are reporting higher use of virtual visits. St. Vincent, for example, sees hundreds of patients a month remotely for ailments ranging from minor rashes and sprains to follow-up visits for strokes.
The Trump administration has finalized regulations that will require drug companies to disclose list prices of medications costing more than $35 for a month’s supply.
Local tech firm, Springbuk, has grown from 16 to 102 employees in a little more than two years. A recently released product upgrade the company is calling “a game changer” is spurring another round of serious growth.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions